The impact of Treosulfan-based conditioning for inborn errors of immunity: Is dose monitoring crucial?

dc.contributor.authorErsoy, Gizem Zengin
dc.contributor.authorÇipe, Funda
dc.contributor.authorFışgın, Tunç
dc.contributor.authorAdaklı Aksoy, Başak
dc.contributor.authorBaşoğlu Öner, Özlem
dc.contributor.authorHashemi, Nazlı
dc.contributor.authorAydoğdu, Selime
dc.contributor.authorErdem, Melek
dc.contributor.authorDikme, Gürcan
dc.contributor.authorMurat, Koza
dc.contributor.authorBozkurt, Ceyhun
dc.date.accessioned2023-08-21T06:26:52Z
dc.date.available2023-08-21T06:26:52Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractIntroduction: In children with inborn errors of immunity (IEI) who will receive a hematopoietic stem cell transplant (HSCT) treosulfan-based conditioning is currently preferred. The aim of this study was to investigate early and late outcomes in pediatric IEI patients receiving pre-HSCT treosulfan and to examine the effect of treosulfan dose monitoring on outcomes. Methods: Seventy-three pediatric patients receiving this management between 2015 and 2022 were included. Results: Overall survival rate was 80%, and event-free survival was 67.8%. A larger treosulfan dose AUC after first application increased the rate of early toxicity (p = .034) and slowed lymphocyte engraftment (r = .290; p = .030). Underlying disease, treosulfan AUC, donor type, stem cell type, number of immunosuppressive agents, the dose of anti-thymocyte globulin, and post-transplantation cyclophosphamide did not to increase risk of acute graft-versus-host disease. The risk of mixed chimerism (MC) in patients with autoimmune lymphoproliferative syndrome and leukocyte adhesion deficiency were higher than those with severe combined immunodeficiency (p = .021 and p = .014, respectively). The risk of MC was lower in those receiving peripheral blood stem cells (SC) compared with bone marrow derived SC (OR = .204, p = .022). Conclusion: The AUC of the treosulfan dose was not associated with poorer late outcomes. Treosulfan is an agent that can be used safely in the IEI patient group, level measurement appears essential to identify early toxicities. Prospective studies with more extended follow-up periods are needed.en_US
dc.identifier.citationErsoy, G. Z., Cipe, F., Fisgin, T., Aksoy, B. A., Oner, O. B., Hashemi, N., ... & Bozkurt, C. (2023). The Impact of Treosulfan-based Conditioning for Inborn Errors of Immunity: Is Dose Monitoring Crucial?. Clinical transplantation, 37(9).en_US
dc.identifier.issn0902-0063
dc.identifier.issn1399-0012
dc.identifier.issue9en_US
dc.identifier.scopus2-s2.0-85166653693
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://hdl.handle.net/20.500.12939/3680
dc.identifier.volume37en_US
dc.identifier.wosWOS:001041668900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorErsoy, Gizem Zengin
dc.institutionauthorFışgın, Tunç
dc.institutionauthorAdaklı Aksoy, Başak
dc.language.isoen
dc.relation.ispartofClinical transplantation
dc.relation.isversionof10.1111/ctr.15083en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDose Monitoringen_US
dc.subjectInborn Errors Of Immunityen_US
dc.subjectStem Cell Transplantationen_US
dc.subjectTreosulfan Conditioningen_US
dc.titleThe impact of Treosulfan-based conditioning for inborn errors of immunity: Is dose monitoring crucial?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Clinical Transplantation - 2023 - Ersoy.pdf
Boyut:
357.54 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: